AAD 2023: Povorcitinib Significantly Improved Total Body Repigmentation in Patients With Extensive Nonsegmental Vitiligo
Oral JAK1 inhibitor met primary endpoint in a phase 2B trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.